This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Buist NRM, Kennaway NG, Fellman JH (1985) Tyrosinaemia type II. In: Bickel H, Wachtel U (eds) Inherited diseases of amino-acid metabolism. Thieme, Stuttgart, pp 203–235
Cerone R, Fantasia AR, Castellano E, Moresco L, Schiaffino MC, Gatti R (2002) Pregnancy and tyrosinaemia type II. J Inherit Metab Dis 25(4):317–318
Chitayat D, Balbul A, Hani V, Mamer OA, Clow C, Scriver CR (1992) Hereditary tyrosinaemia type II in a consanguineous Ashkenazi Jewish family: intrafamilial variation in phenotype; absence of parental phenotype effects on the fetus. J Inherit Metab Dis 15(2):198–203
Ellaway CJ, Holme E, Standing S, Preece MA, Green A, Ploechl E, Ugarte M, Trefz FK, Leonard JV (2001) Outcome of tyrosinaemia type III. J Inherit Metab Dis 24(8):824–832
Francis DE, Kirby DM, Thompson GN (1992) Maternal tyrosinaemia II: management and successful outcome. Eur J Pediatr 151(3):196–199
Haas V de, Carbasius Weber EC, Klerk JB de, Bakker HD, Smit GP, Huijbers WA, Duran M, Poll-The BT (1998) The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis 21(8):791–798
Holme E, Lindstedt S (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 21(5):507–517
Holme E, Lindstedt S (2000) Nontransplant treatment of tyrosinemia. Clin Liver Dis 4(4):805–814
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817
Mitchell G, Grompe M, Lambert M, Tanguay (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, pp 1777–1805
Morava E, Kosztolanyi G, Engelke UF, Wevers RA (2003) Reversal of clinical symptoms and radiographic abnormalities with protein restriction and ascorbic acid in alkaptonuria. Clin Biochem 40(1):108–111
Paige DG, Clayton P, Bowron A, Harper JI (1992) Richner-Hanhart syndrome (oculocutaneous tyrosinaemia, tyrosinaemia type II). J R Soc Med 85(12):759–760
Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA (2002) Natural history of alkaptonuria. N Engl J Med 347(26):2111–2121
Spronsen FJ van, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, Berger R, Heymans HS (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20(5):1187–1191
Wilcken B, Hammond JW, Howard N, Bohane T, Hocart C, Halpern B (1981) Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy. N Engl J Med 305(15):865–868
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Holme, E. (2006). Disorders of Tyrosine Degradation. In: Blau, N., Leonard, J., Hoffmann, G.F., Clarke, J.T.R. (eds) Physician’s Guide to the Treatment and Follow-Up of Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28962-3_6
Download citation
DOI: https://doi.org/10.1007/3-540-28962-3_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22954-4
Online ISBN: 978-3-540-28962-3
eBook Packages: MedicineMedicine (R0)